The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia

Nückel, H.; Switala, M.; Sellmann, L.; Horn, P. A.; Dürig, J.; Dührsen, U.; Küppers, R.; Grosse-Wilde, H.; Rebmann, V.
June 2010
Leukemia (08876924);Jun2010, Vol. 24 Issue 6, p1152
Academic Journal
Soluble or membrane-anchored ligands of NKG2D and their receptor have a critical role in the elimination of tumor cells and disease progression. Plasma samples of 98 patients with B-cell chronic lymphocytic leukemia (CLL) were analyzed with specific ELISA systems for soluble major histocompatibility complex class I-related chains (sMICA and sMICB) and UL-16-binding proteins (ULBP1, 2, and 3). The flow cytometric analysis of MICA on CLL cells and natural killer group 2 member D (NKG2D) receptors on NK cells was performed after thawing of frozen peripheral blood lymphocytes of CLL patients (N=51). Levels of sMICA, sMICB, and sULBP2 were significantly increased (P<0.001) compared with 48 controls, whereas sULBP1 3 were not detectable in patients and controls. Levels of sMICA>990 pg/ml (P=0.014), sMICB>200 pg/ml (P=0.0001), and sULBP2>105 pg/ml (P<0.0001) were associated with poor treatment-free survival (TFS). Neither MICA nor NKG2D expression could be related to clinical parameters. In multivariate analysis Binet stage (P=0.002), sULBP2 (P=0.002) and ZAP-70 (P=0.002) were independent predictive factors for TFS. In patients with Binet stage A, sULBP2 levels>105 pg/ml were strongly associated (P=0.0025) with poor TFS. Our data show that soluble but not membrane-anchored NKG2D ligands or receptors are of prognostic significance in CLL. Moreover, sULBP2 seems to be useful to identify early-stage patients with risk of disease progression.


Related Articles

  • Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia. Loisel, Séverine; Le Ster, Karine; Meyer, Michèle; Berthou, Christian; Youinou, Pierre; Kolb, Jean-Pierre; Billard, Christian // Journal of Hematology & Oncology;2010, Vol. 3, p49 

    Background: We previously reported that allanxanthone C and macluraxanthone, two xanthones purified from Guttiferae trees, display in vitro antiproliferative and proapoptotic activities in leukemic cells from chronic lymphocytic leukemia (CLL) and leukemia B cell lines. Results: Here, we...

  • Chronic Lymphocytic Leukemia (B-CLL). Jurlander, Jesper // Encyclopedic Reference of Cancer;2001, p207 

    An encyclopedia entry for "chronic lymphocytic leukemia" is presented. It refers to the adult form of leukemia with systemic accumulation of mature B-lymphocytes, derived from a subset of CD5-positive B-lymphocytes. It is the most common form of leukemia in the western hemisphere and is rarely...

  • A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. Calin, George Adrian; Ferracin, Manuela; Cimmino, Amelia; Di Leva, Gianpiero; Shimizu, Masayoshi; Wojcik, Sylwia E.; Iorio, Marilena V.; Visone, Rosa; Sever, Nurettin Ilfer; Fabbri, Muller; Iuliano, Rodolfo; Palumbo, Tiziana; Pichiorri, Flavia; Roldo, Claudia; Garzon, Ramiro; Sevignani, Cinzia; Rassenti, Laura; Alder, Hansjuerg; Volinia, Stefano; Liu, Chang-gong // New England Journal of Medicine;10/27/2005, Vol. 353 Issue 17, p1793 

    Background: MicroRNA expression profiles can be used to distinguish normal B cells from malignant B cells in patients with chronic lymphocytic leukemia (CLL). We investigated whether microRNA profiles are associated with known prognostic factors in CLL. Methods: We evaluated the microRNA...

  • Flavopiridol: where do we stand in chronic lymphocytic leukemia? Lin, T.S.; Porcu, P. // Leukemia (08876924);Feb2004, Vol. 18 Issue 2, p243 

    Identifies flavopiridol's mechanism of action in B-cell chronic lymphocytic leukemia (B-CLL). Mechanisms by which flavopiridol induces apoptosis in B-CLL cells; Characteristics of flavopiridol; Source of B-CLL cells' inherent resistance to traditional cytotic therapy; Need for continued...

  • Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Hoogendoorn, M.; Wolbers, J. Olde; Smit, W.M.; Schaafsma, M.R.; Barge, R.M.Y.; Willemze, R.; Falkenburg, J.H.F. // Leukemia (08876924);Jul2004, Vol. 18 Issue 7, p1278 

    Allogeneic stem cell transplantation following reduced-intensity conditioning is being evaluated in patients with advanced B-cell chronic lymphocytic leukemia (B-CLL). The curative potential of this procedure is mediated by donor-derived alloreactive T cells, resulting in a graft-versus-leukemia...

  • Ig V region restrictions in human chronic lymphocytic leukemia suggest some cases have a common origin. Kolar, Grant R.; Copra, J. Donald // Journal of Clinical Investigation;Apr2004, Vol. 113 Issue 7, p952 

    The factors that contribute to the development of B cell chronic lymphocytic leukemia (B-CLL) are unknown, and the groups of individuals at the greatest risk for developing this common leukemia are not well defined. Molecular features are important for classifying cases of B-CLL, and it is now...

  • Usefulness of CD45 density in the diagnosis of B-cell chronic lymphoproliferative disorders. Maljaei, Seyyed Hadi; Asvadi-E-Kermani, Iraj; Eivazi-E-Ziaei, Jamal; Nikanfar, Alireza; Vaez, Jalil // Indian Journal of Medical Sciences;May2005, Vol. 59 Issue 5, p187 

    Background: Although many B-cell chronic lymphoproliferative disorders (BCLPDs) including B-cell chronic lymphocytic leukemia (B-CLL) have characteristic clinical and biological features, the overlapping morphologic and immunophenotypic profiles of various BCLPDs, is still the main...

  • ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia. Rassenti, Laura Z.; Huynh, Lang; Toy, Tracy L.; Chen, Liguang; Keating, Michael J.; Gribben, John G.; Neuberg, Donna S.; Flinn, Ian W.; Rai, Kanti R.; Byrd, John C.; Kay, Neil E.; Greaves, Andrew; Weiss, Arthur; Kipps, Thomas J. // New England Journal of Medicine;8/26/2004, Vol. 351 Issue 9, p893 

    Background: The course of chronic lymphocytic leukemia (CLL) is variable. In aggressive disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-region gene (IgV) and the 70-kD zeta-associated protein (ZAP-70), whereas in indolent disease, the CLL cells usually...

  • Subject Index.  // Immunology & Cell Biology;Dec1991, Vol. 69 Issue 6, p431 

    The article presents an index to several topics that have been discussed in the December 1991 issue of the journal "Immunology and cell Biology." Some of the topics are autoimmune and normal mice: arachadonic acid metabolites and lymphocyte-high endothelial venule interactions, B cells in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics